Log In
Print this Print this

TT701 (formerly LY2452473)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionSelective androgen receptor modulator (SARM)
Molecular Target Androgen receptor
Mechanism of ActionSelective androgen receptor modulator (SARM)
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationAndrogen deficiency
Indication DetailsTreat androgen deficiency in men with prostate cancer who have undergone radical prostatectomy
Regulatory Designation
PartnerOpko Health Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today